LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris

Inclusion Criteria: * Age 18 years or above * Psoriasis vulgaris on the trunk and/or limbs (excluding psoriasis on the genitals and skin folds) involving 2-30% of the Body Surface Area (BSA) * A Physician's Global Assessment of disease severity (PGA) of at least mild on trunk and limbs * A modified Psoriasis Area Severity Index (PASI) score of at least 2 on the trunk and limbs. Exclusion Criteria: * Current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis * Systemic treatment with biological therapies, whether marketed or not, with a possible effect on psoriasis vulgaris within the following time periods prior to randomisation: * etanercept - within 4 weeks prior to randomisation * adalimumab, infliximab - within 8 weeks prior to randomisation * ustekinumab - within 16 weeks prior to randomisation * other products - within 4 weeks/5 half-lives prior to randomisation (whichever is longer) * Systemic treatment with all other therapies with a possible effect on psoriasis vulgaris (e.g. corticosteroids, retinoids, methotrexate, ciclosporin and other immunosuppressants within 4 weeks prior to randomisation) * Subjects who have received treatment with any non-marketed drug substance (i.e. a drug which has not yet been made available for clinical use following registration) within 4 weeks/5 half-lives (whichever is longer) prior to randomisation. * Psoralen combined with Ultraviolet A (PUVA) therapy within 4 weeks prior to randomisation * Ultraviolet B (UVB) therapy within 2 weeks prior to randomisation * Topical anti-psoriatic treatment on the trunk and limbs (except for emollients) within 2 weeks prior to randomisation * Topical treatment on the face, scalp and skin folds with corticosteroids, vitamin D analogues or prescription shampoos within 2 weeks prior to randomisation * Females who are pregnant, wishing to become pregnant during the trial or are breastfeeding